Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Dispositivo de Terapia con Luz Infrarroja Cercana para la Enfermedad de Alzheimer Leve-Moderada (NirsCure-03A)

17 de septiembre de 2026 actualizado por: Danyang Huichuang Medical Equipment Co., Ltd.

Un Estudio Multicéntrico, Aleatorizado, Doble Ciego y Controlado con Simulacro sobre la Eficacia y Seguridad de un Dispositivo de Terapia con Luz Infrarroja Cercana en Participantes con Enfermedad de Alzheimer Leve-Moderada (NirsCure-03A)

This study is a multicenter, randomized, double-blind, sham-device-controlled clinical trial.

A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and Aβ-PET subgroup center status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home during a 52-week double-blind period. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the double-blind period. Participants who complete the 52-week double-blind treatment period may choose to enter an open-label extension and receive an additional 26 weeks of active near-infrared light therapy.

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

320

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yi Tang, MD, PhD
  • Número de teléfono: +86 13811021432
  • Correo electrónico: tangyi@xwhosp.org

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100191
        • Reclutamiento
        • Peking University Third Hospital
        • Contacto:
          • Weizhong Xiao, MD, PhD
          • Número de teléfono: +86 15611908691
      • Beijing, Beijing Municipality, Porcelana, 100053
        • Reclutamiento
        • Xuanwu Hospital, Capital Medical University
        • Contacto:
          • Yi Tang, MD, PhD
          • Número de teléfono: +86 13811021432
          • Correo electrónico: tangyi@xwhosp.org
      • Beijing, Beijing Municipality, Porcelana, 100032
        • Reclutamiento
        • Peking University First Hospital
        • Contacto:
          • Yongan Sun, MD, PhD
          • Número de teléfono: +86 13391705678
      • Beijing, Beijing Municipality, Porcelana, 100730
        • Reclutamiento
        • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
        • Contacto:
          • Jing Yuan, MD, PhD
          • Número de teléfono: +86 18601105034
      • Beijing, Beijing Municipality, Porcelana, 100050
        • Reclutamiento
        • Beijing Friendship Hospital, Capital Medical University
        • Contacto:
          • Yongbo Zhang, MD, PhD
          • Número de teléfono: +86 13552909549
    • Hebei
      • Shijiazhuang, Hebei, Porcelana, 050000
        • Reclutamiento
        • Shijiazhuang People's Hospital
        • Contacto:
          • Jianping Zhang, MD, PhD
          • Número de teléfono: +86 17603116783
    • Inner Mongolia
      • Baotou, Inner Mongolia, Porcelana, 014040
        • Reclutamiento
        • Baotou Central Hospital
        • Contacto:
          • Furu Liang, MD, PhD
          • Número de teléfono: +86 13664077877
    • Jiangsu
      • Suzhou, Jiangsu, Porcelana, 215006
        • Reclutamiento
        • The First Affiliated Hospital of Soochow University
        • Contacto:
          • Qun Xue, MD, PhD
          • Número de teléfono: +86 13013813620
      • Suzhou, Jiangsu, Porcelana, 215004
        • Reclutamiento
        • The Second Affiliated Hospital of Soochow University
        • Contacto:
          • Chunfeng Liu, MD, PhD
          • Número de teléfono: +86 13606210609
    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 710061
        • Reclutamiento
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Contacto:
          • Jin Wang, MD, PhD
          • Número de teléfono: +86 13572208524
      • Xi'an, Shaanxi, Porcelana, 710068
        • Reclutamiento
        • Shaanxi Provincial People's Hospital
        • Contacto:
          • Rui Li, MD, PhD
      • Xi'an, Shaanxi, Porcelana, 710038
        • Reclutamiento
        • Tangdu Hospital, Air Force Medical University
        • Contacto:
          • Wei Zhang, MD, PhD
          • Número de teléfono: +86 13891955100
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200127
        • Reclutamiento
        • Renji Hospital, Shanghai Jiao Tong University School of Medicine
        • Contacto:
          • Qun Xu, MD, PhD
          • Número de teléfono: +86 13301679717
      • Shanghai, Shanghai Municipality, Porcelana, 200040
        • Reclutamiento
        • Huashan Hospital, Fudan University
        • Contacto:
          • Qianhua Zhao, MD, PhD
      • Shanghai, Shanghai Municipality, Porcelana, 200030
        • Reclutamiento
        • Shanghai Mental Health Center
        • Contacto:
          • Xia Li, MD, PhD
          • Número de teléfono: +86 13774272543
      • Shanghai, Shanghai Municipality, Porcelana, 201399
        • Reclutamiento
        • Pudong Hospital, Fudan University
        • Contacto:
          • Yunxia Li, MD, PhD
          • Número de teléfono: +86 13636370312
    • Shanxi
      • Taiyuan, Shanxi, Porcelana, 030001
        • Reclutamiento
        • The First Hospital of Shanxi Medical University
        • Contacto:
          • Yang Li, MD, PhD
          • Número de teléfono: +86 15035182003
      • Taiyuan, Shanxi, Porcelana, 030001
        • Reclutamiento
        • Shanxi Bethune Hospital
        • Contacto:
          • Xiaolei Liu, MD, PhD
          • Número de teléfono: +86 13934643261
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300052
        • Reclutamiento
        • General Hospital, Tianjin Medical University
        • Contacto:
          • Nan Zhang, MD, PhD
          • Número de teléfono: +86 13752128310
      • Tianjin, Tianjin Municipality, Porcelana, 300060
        • Reclutamiento
        • Tianjin Huanhu Hospital
        • Contacto:
          • Pan Li, MD, PhD
          • Número de teléfono: +86 13114881943
      • Tianjin, Tianjin Municipality, Porcelana, 300121
        • Reclutamiento
        • Tianjin People's Hospital
        • Contacto:
          • Meiyun Zhang, MD, PhD
          • Número de teléfono: +86 13102017703
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310009
        • Reclutamiento
        • The Second Affiliated Hospital, Zhejiang University School of Medicine
        • Contacto:
          • Baorong Zhang, MD, PhD
          • Número de teléfono: +86 13958167260
      • Hangzhou, Zhejiang, Porcelana, 310015
        • Reclutamiento
        • Affiliated Hospital of Hangzhou Normal University
        • Contacto:
          • Jinghua Wang, MD, PhD
          • Número de teléfono: +86 15068892292

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

50 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female participants aged between 50 to 85 years old (inclusive).

  2. Participants must have at least 4 years of formal education and be capable of completing cognitive and other protocol-specified assessments.

  3. Documented progressive memory decline for ≥12 months prior to screening.

  4. Meets the core clinical diagnostic criteria for mild to moderate AD dementia (stages 4-5), according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) 2018 research framework and the AA workgroup 2024 update.

  5. Evidence of positive brain amyloid pathology, demonstrated by at least one of the following:

    1. Positive Aβ-PET scan (historical positive result acceptable); or
    2. Positive Cerebrospinal fluid (CSF) Aβ testing (historical positive result acceptable).
  6. Mini-Mental State Examination (MMSE) total score between 15 and 26 inclusive (between 12 and 22 for participants with an elementary school education level).

  7. Clinical Dementia Rating (CDR) Global of 1 or 2, and the CDR-Memory Box scores ≥ 0.5.

  8. If receiving acetylcholinesterase inhibitor or memantine, participants must be on a stable dose for at least 12 weeks prior to baseline.

  9. Must have at least one reliable study partner who can accompany the participant to complete daily treatment. The study partner should have a close relationship with the participant and sufficient knowledge to accurately report on cognition, function, behavior, safety, and protocol compliance. The study partner must be able to communicate with study staff via phone or WeChat, attend required on-site visit, provide informed consent to supporting follow-up throughout the study.

  10. The participant, study partner, or legally authorized representative voluntarily agrees to participate and provides written informed consent prior to any study procedures.

Exclusion Criteria:

  1. Presence of any diagnosis other than AD that could cause dementia or cognitive decline, including but not limited to: vascular dementia; Central nervous system infections (e.g., HIV, neurosyphilis); Creutzfeldt-Jakob disease; Huntington's disease; Parkinson's disease; Lewy body dementia; Traumatic brain injury-related dementia; Dementia caused by physical and chemical factors (e.g., drug toxicity, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic or pulmonary encephalopathy); Intracranial space-occupying lesions (e.g., subdural hematoma, brain tumors); or dementia clearly attributable to endocrine disorders, vitamin deficiencies, or other identifiable causes.

  2. Brain MRI demonstrating significant pathological findings, including but not limited to:

    1. More than two infarcts with a diameter > 2 cm, or a single infarct involving critical regions (thalamus, hippocampus, entorhinal cortex, parahippocampal cortex, angular gyrus, or other cortical and subcortical gray matter nuclei);
    2. Extensive white matter hyperintensities (Fazekas score ≥ 3);
    3. Space-occupying lesions such as abscesses or brain tumors. Lesions judged by the investigator to have no clear clinical significance do not require exclusion.
  3. History of transient ischemic attack (TIA), stroke, or seizure within 6 months of screening.

  4. Hachinski Ischemic Score (HIS) > 4.

  5. Hamilton Depression Rating Scale (HAMD-17) total score > 10.

  6. Diagnosis of a psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) at screening, including schizophrenia or other psychotic disorders, bipolar disorder, major depressive disorder, or delirium.

  7. Known history or laboratory confirmation of HIV infection or neurosyphilis at screening.

  8. Severe cardiovascular disease, including New York Heart Association (NYHA) class III or IV heart function; Severe or unstable angina, or newly developed unstable angina within 3 months prior to screening (with objective clinical evidence such as cardiac enzyme abnormalities or dynamic ST-T changes on electrocardiogram); Acute myocardial infarction within 6 months prior to screening.

  9. Severe dysfunction of major organs (heart, lungs, liver, kidneys, etc.), or any medical condition that, in the opinion of the investigator, could render the participant unsuitable for this study or interfere with participation.

  10. Current or prior treatment with any anti-amyloid monoclonal antibody (e.g., aducanumab, lecanemab, or donanemab).

  11. Prior or planned lymphaticovenous anastomosis (LVA) of the cervical deep lymphatic vessels.

  12. Participation in any interventional clinical trial involving a drug or medical device within the 30 days prior to screening, except for observational studies or verified placebo-group participation in a previous interventional trial.

  13. History of severe head trauma or implanted cranial devices (e.g., bone screws, bone plates, prior cranial surgery, deep brain stimulators); Contraindications to MRI (e.g., claustrophobia, pacemakers/defibrillators, ferromagnetic metal implants); unwilling to undergo MRI examination.

  14. Contraindications to PET or allergy to Aβ-PET tracer (except participants enrolled based solely on CSF Aβ positivity). Participants with uncontrolled abnormal blood glucose, allergy to FDG tracer, or any other investigator-judged contraindications are ineligible for the FDG-PET substudy.

  15. History of malignancy within 5 years prior to screening, except for:

    1. Adequately treated basal or squamous cell skin carcinoma, or cervical dysplasia;
    2. Adequately treated Stage I in situ cervical cancer ≥ 2 years prior to screening without recurrence;
    3. Prostate cancer confined to the prostate, adequately treated (e.g., surgery, radiotherapy, or active surveillance), with stable prostate-specific antigen (PSA) levels for ≥ 2 years prior to screening;
    4. Non-metastatic breast cancer, adequately treated and without recurrence.
  16. Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential not using highly effective contraception.

  17. Any other condition that, in the opinion of the investigator, may compromise the participant's safety, interfere with protocol adherence, or confound study results.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador falso: Sham device

Device: NirsCure 6000 sham device (once daily for 30 minutes, six times per week)

Sham device for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive active near-infrared light therapy for an additional 26 weeks.

Experimental: Near infrared light therapy

Device: NirsCure 6000 Near-infrared light therapy (once daily for 30 minutes, six times per week)

Near-infrared light therapy for 52 weeks during the double-blind period (once daily for 30 minutes, six times per week). Participants entering the open-label extension will receive an additional 26 weeks of active treatment with the same regimen.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Alzheimer's Disease Assessment Scale, cognitive subscale 13 (ADAS-Cog13)
Periodo de tiempo: 52 weeks

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) score at 52-Weeks. The ADAS-Cog13 score ranges from 0 to 85, with higher scores indicating greater cognitive impairment.

52 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Integrated Alzheimer's Disease Rating Scale (iADRS)
Periodo de tiempo: 52 weeks

Change from baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) score at 52-Weeks. The iADRS score ranges from 0 to 144, with higher scores indicating better overall cognitive and functional performance.

52 weeks
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL)
Periodo de tiempo: 52 weeks

Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at 52-Weeks. The ADCS-ADL score ranges from 0 to 78, with higher scores indicating better functional ability in activities of daily living.

52 weeks
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Periodo de tiempo: 52 weeks

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at 52-Weeks. The CDR-SB score ranges from 0 to 18, with higher scores indicating greater cognitive and functional impairment.

52 weeks
Mini-Mental Status Examination (MMSE)
Periodo de tiempo: 52 weeks

Change from baseline in Mini-Mental State Examination (MMSE) score at 52-Weeks. The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive function.

52 weeks
ADAS-Cog13
Periodo de tiempo: 13, 26 and 39 weeks

Change from baseline in the ADAS-Cog13 at Week 13, 26 and 39

13, 26 and 39 weeks
ADAS-Cog13
Periodo de tiempo: 81 weeks

Change from baseline in the ADAS-Cog13 at Week 81

81 weeks
iADRS
Periodo de tiempo: 81 weeks

Change from baseline in the iADRS at Week 81

81 weeks
ADCS-ADL
Periodo de tiempo: 81 weeks

Change from baseline in the ADCS-ADL at Week 81

81 weeks
CDR-SB
Periodo de tiempo: 81 weeks

Change from baseline in the CDR-SB at Week 81

81 weeks
MMSE
Periodo de tiempo: 81 weeks

Change from baseline in the MMSE at Week 81

81 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de diciembre de 2025

Finalización primaria (Estimado)

22 de julio de 2027

Finalización del estudio (Estimado)

22 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

1 de diciembre de 2025

Publicado por primera vez (Actual)

3 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NirsCure-03A

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir